207 Ch 207. Respiratory Syncytial Virus (RSV)

Universal childhood infection (95%+ by 2 yr); leading cause of bronchiolitis + pediatric LRTI; severe in infants < 6 mo + elderly ≥ 65 + immunocompromise; 2023 trio of new prophylaxis/vaccines: nirsevimab (mAb), maternal RSVpreF, adult vaccines (Arexvy, Abrysvo, mRESVIA mRNA); palivizumab being replaced; supportive care core treatment。